---
title: "Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Dosage"
description: "Formulary evidence on Lorundrostat (MLS-101, MT-4129) in Hypertension, in combination with other antihypertensive drugs: Dosage. Topics: Launch-HTN: 50 mg once daily, with escalation to 100 mg at week 6 in one group; Advance-HTN: 50 mg once daily, or 50 mg increased to 100 mg after 4 weeks; Target-HTN: dose-ranging from 12.5 mg once daily to 100 mg once daily; Transform-HTN: 50 mg once daily, or 25 mg after a dose reduction; 3 further topics. 7 evidence topics quoted from 7 sources."
canonical: "https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/product-information-and-disease-description/dosage"
published: "2026-11-18T10:43:00-05:00"
modified: "2026-11-18T10:43:00-05:00"
---

# Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Dosage

<a id="heading-2.1.2.10.1"></a>

## 2.1.2.10.1 Dosage

<a id="topic-2.1.2.10.1-1"></a>

### Launch-HTN: 50 mg once daily, with escalation to 100 mg at week 6 in one group

> “participants were randomly assigned in a 1:2:1 ratio to receive 50 mg of lorundrostat for 6 weeks and then possibly 100 mg for 6 weeks (n = 270) if they met prespecified criteria at week 6 (the prespecified criteria were office systolic BP ≥130 mm Hg, serum potassium level ≤4.8 mmol/L, serum sodium level ≥135 mmol/L, eGFR >45 mL/min/1.73 m2, and <25% reduction in eGFR from baseline), 50 mg of lorundrostat once daily for 12 weeks (n = 541), or placebo once daily for 12 weeks (n = 272).”
> “Of the 270 participants randomized to 50 mg of lorundrostat once daily, 92 (34.1%) were escalated to the 100-mg dose.”
> “The trial medication dose could be reduced, temporarily withheld, or permanently discontinued for safety concerns at the discretion of the investigators.”
> “Increasing the 50-mg/d dose of lorundrostat to 100 mg/d provided no additional benefit to participants who did not reach the goal BP using the 50-mg/d dose.”

Source: [Saxena et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210145/)

<a id="topic-2.1.2.10.1-2"></a>

### Advance-HTN: 50 mg once daily, or 50 mg increased to 100 mg after 4 weeks

> “participants with an average 24-hour ambulatory blood pressure of 130/80 mm Hg or higher were assigned to receive placebo, lorundrostat at a stable dose of 50 mg daily (the stable-dose group), or lorundrostat at a starting dose of 50 mg daily, with an increase to 100 mg daily if systolic blood pressure was 130 mm Hg or higher after 4 weeks (the dose-adjustment group).”

Source: [Laffin et al. (2025b)](https://pubmed.ncbi.nlm.nih.gov/40267417/)

<a id="topic-2.1.2.10.1-3"></a>

### Target-HTN: dose-ranging from 12.5 mg once daily to 100 mg once daily

> “Cohort 1 participants were randomly assigned in a 1:1:1:1:1:1 ratio to placebo or 1 of 5 lorundrostat doses (12.5 mg, 50 mg, or 100 mg once daily or 12.5 mg or 25 mg twice daily).”
> “randomization to the 2 lowest doses of lorundrostat (12.5 mg once daily and 12.5 mg twice daily) was discontinued due to lack of consistent meaningful reduction of BP.”
> “The 50-mg once-daily dose of lorundrostat lowered office BP to a similar degree as the 100-mg once daily dose, but resulted in fewer adverse events, including fewer episodes of hyperkalemia.”

Source: [Laffin et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10493865/)

<a id="topic-2.1.2.10.1-4"></a>

### Transform-HTN: 50 mg once daily, or 25 mg after a dose reduction

> “The open-label starting lorundrostat dose was 50 mg once daily, or 25 mg if the previously blinded treatment dose was reduced.”

Source: [Mineralys Therapeutics press release, Transform-HTN results (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/129/mineralys-therapeutics-presents-new-late-breaking-data-from)

<a id="topic-2.1.2.10.1-5"></a>

### Explore-CKD: 25 mg once daily

> “4-week treatment with oral lorundrostat 25 mg once daily”

Source: [Weir et al. (2026)](https://doi.org/10.1016/j.kint.2026.08.021)

<a id="topic-2.1.2.10.1-6"></a>

### Explore-OSA: 50 mg once daily in the evening

> “evaluated the safety and efficacy of lorundrostat 50 mg QD administered in the evening in 48 participants with hypertension and moderate-to-severe OSA”

Source: [Mineralys Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1933414/000193341426000056/mlys-20251231.htm)

<a id="topic-2.1.2.10.1-7"></a>

### Doses evaluated in healthy participants

> “The dosing cohorts were 5, 10, 20, 50, 100, 200, 400, and 800 mg”
> “The final dose levels of lorundrostat for part 2 were 40, 120, and 360 mg.”

Source: [Shimizu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11329366/)

<a id="topic-2.1.2.10.1-8"></a>

### Proposed labeled dose

No evidence found.

## Related pages
- [Lorundrostat (MLS-101): Hypertension, in combination with other antihypertensive drugs](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Terms and abbreviations](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/terms-and-abbreviations.md)
- [Lorundrostat (MLS-101): Hypertension, in combination with other antihypertensive drugs](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/executive-summary.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Product information and disease description](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/product-information-and-disease-description.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Clinical evidence](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/clinical-evidence.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Economic information and modeling report](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/economics) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/economics.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: References](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/references) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/references.md)
